Citations (13)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Kentaro Kogushi, Toshio Ogawa & Shunya Ikeda. (2020) An impact analysis of the implementation of health technology assessment for new treatment of orphan diseases in Japan. Expert Review of Pharmacoeconomics & Outcomes Research 20:5, pages 455-471.
Read now
Read now
Maria Kamusheva, Konstantin Tachkov, Guenka Petrova, Alexandra Savova & Manoela Manova. (2018) Orphan medicinal products’ access to the Bulgarian pharmaceutical market – challenges and obstacles. Expert Opinion on Orphan Drugs 6:2, pages 95-104.
Read now
Read now
Articles from other publishers (11)
Małgorzata Skweres-Kuchta, Iwona Czerska & Elżbieta Szaruga. (2023) Literature Review on Health Emigration in Rare Diseases—A Machine Learning Perspective. International Journal of Environmental Research and Public Health 20:3, pages 2483.
Crossref
Crossref
Ahmad Nader Fasseeh, Sarah Maria Saragih, Noha Hayek, Sasha Brodovska, Adham Ismail, Amr ElShalakani, Sherif Abaza, George Dennis Obeng, David Ameyaw & Zoltan Kalo. (2022) Impact of health technology assessment implementation with a special focus on middle-income countries. Health Policy and Technology 11:4, pages 100688.
Crossref
Crossref
Reineke A. Schoot, Maria A. Otth, Gerardus W.J. Frederix, Hubert G.M. Leufkens & Gilles Vassal. (2022) Market access to new anticancer medicines for children and adolescents with cancer in Europe. European Journal of Cancer 165, pages 146-153.
Crossref
Crossref
Yitong Wang, Tingting Qiu, Mateusz Nikodem, Clément Francois & Mondher Toumi. (2022) A systematic literature review of revealed preferences of decision-makers for recommendations of cancer drugs in health technology assessment. International Journal of Technology Assessment in Health Care 38:1.
Crossref
Crossref
Ramon Schaefer, Diego Hernandez, Lorenz Selberg & Michael Schlander. (2021) Health technology assessment (HTA) in England, France and Germany: what do matched drug pairs tell us about recommendations by national HTA agencies?. Journal of Comparative Effectiveness Research 10:16, pages 1187-1195.
Crossref
Crossref
Isaac Aranda-Reneo, Beatriz Rodríguez-Sánchez, Luz María Peña-Longobardo, Juan Oliva-Moreno & Julio López-Bastida. (2021) Can the Consideration of Societal Costs Change the Recommendation of Economic Evaluations in the Field of Rare Diseases? An Empirical Analysis. Value in Health 24:3, pages 431-442.
Crossref
Crossref
James Keech, Wei Fang Dai, Maureen Trudeau, Rebecca E. Mercer, Rohini Naipaul, Frances C. Wright, Sarah E. Ferguson, Gail Darling, Scott Gavura, Andrea Eisen, C. Tom Kouroukis, Jaclyn Beca & Kelvin K.W. Chan. (2020) Impact of rarity on Canadian oncology health technology assessment and funding. International Journal of Technology Assessment in Health Care 36:4, pages 404-409.
Crossref
Crossref
Lefteris Floros, Daniel Kuessner, Jan Posthumus, Emma Bagshaw & Jan Sjölin. (2019) Cost-effectiveness analysis of isavuconazole versus voriconazole for the treatment of patients with possible invasive aspergillosis in Sweden. BMC Infectious Diseases 19:1.
Crossref
Crossref
Arvin M. Gouw, Lipika R. Pal, Debora Varon, Danielle C. Fumagalli & Anita Chacko. 2019. Genomics and Clinical Diagnostics. Genomics and Clinical Diagnostics
212
225
.
John I. McCormick, L. Diana Berescu & Nabil Tadros. (2018) Common drug review recommendations for orphan drugs in Canada: basis of recommendations and comparison with similar reviews in Quebec, Australia, Scotland and New Zealand. Orphanet Journal of Rare Diseases 13:1.
Crossref
Crossref
Krzysztof Piotr Malinowski, Paweł Kawalec, Wojciech Trabka, Christoph Sowada & Andrzej Pilc. (2018) Reimbursement of Orphan Drugs in Europe in Relation to the Type of Authorization by the European Medicines Agency and the Decision Making Based on Health Technology Assessment. Frontiers in Pharmacology 9.
Crossref
Crossref